Topic: Gw Pharma

GW Pharmaceuticals is bringing Sativex, a liquid cannabinoid medicine, to market. The discussion suggests that the current crackdown on independent medical marijuana dispensaries is a coordinated effort to transition the industry into the hands of approved pharmaceutical dealers. This shift is viewed as a financial strategy to benefit corporate interests and political donors.